Effectiveness of Antiviral Therapy
We set SVR rates for standard therapy to the average
of that reported in 4 studies of antiviral therapy administered
in primary care settings, yielding an SVR rate of 0.33
for genotypes 1/4 and 0.69 for genotypes 2/3 (17, 22, 43,
52). We set the SVR rate for DAA plus standard therapy to
0.54, a value equal to the ratio of the average SVR rate of
standard therapy (0.33) divided by the SVR of standard
therapy observed in clinical trials (0.46) multiplied by the
SVR rate observed for 12-week DAA plus PEG-IFNR
treatment in clinical trial data (0.75) (32).